pde-6 Antibody

Definition and Target Specificity

PDE6 antibodies are polyclonal or monoclonal reagents that bind to specific subunits of the PDE6 enzyme. PDE6 exists as two isoforms:

• Rod PDE6: Heterotetrameric complex (αβ catalytic dimer + two inhibitory γ subunits; encoded by PDE6A, PDE6B, and PDE6G genes) .

• Cone PDE6: Homodimeric catalytic α’ subunits + cone-specific γ’ subunits (encoded by PDE6C and PDE6H) .

Key Targets of PDE6 Antibodies

Applications in Research

PDE6 antibodies are widely used in:

• Immunohistochemistry (IHC): Localize PDE6 in retinal tissues (e.g., human rectal cancer, rat retina) .

• Western Blot (WB): Detect PDE6 subunits in lysates (e.g., MCF-7 breast cancer cells) .

• Flow Cytometry: Quantify PDE6 expression in cell lines (e.g., A549 cells) .

• Immunofluorescence (IF): Visualize PDE6 in CACO-2 and A431 cells .

Example Protocol (IHC for PDE6α):

1. Antigen Retrieval: EDTA buffer (pH 8.0).

2. Blocking: 10% goat serum.

3. Primary Antibody: 1 μg/mL rabbit anti-PDE6α (A07800-1) .

4. Detection: Biotinylated secondary antibody + DAB chromogen .

3.2. Disease Associations

• Retinal Degeneration: Mutations in PDE6A/B cause retinitis pigmentosa and congenital stationary night blindness .

• Breast Cancer: PDE6β is overexpressed in ductal/lobular carcinomas (16/16 cases studied) .

Table: PDE6 Expression in Disease Models

Comparative Studies

• Subunit Affinity: Cone PDE6γ’ exhibits higher binding affinity for PDE6α’ than rod PDE6γ, enhancing holoenzyme stability .

• Therapeutic Potential: AAV-mediated delivery of PDE6α’ rescues photoreceptor function in rd10 mice .

Clinical Implications

• Diagnostics: PDE6 antibodies aid in detecting retinal dystrophies and cancer biomarkers .

• Drug Development: Targeting PDE6γ interactions with Gα* or RGS9-1 could treat PDE6-linked retinopathies .

Limitations and Future Directions

• Challenges: Heterologous expression of functional PDE6 requires chaperones like AIPL1 .

• Opportunities: High-resolution structures (via cryo-EM) may enable small-molecule therapies for PDE6 mutations .